Tech-fueled philanthropy is responsible for one of the most promising new mental health innovations as the Food and Drug Administration is on the verge of allowing doctors to prescribe therapy with the psychedelic drugs in ecstasy and “magic mushrooms” in order to treat severe depression. Though initial studies with psychedelics have been successful enough for the FDA to grant a rare “breakthrough” waiver to accelerate their adoption through an otherwise lengthy regulatory process, government agencies and members of Congress have not supported further research. Nearly all research funding has come from wealthy philanthropists, such as venture capitalist George Sarlow, […]
Full Post at www.brookings.edu